Introduction
Recent research published by JAMA Network highlights the ongoing challenges in lung cancer screening across the United States. The study reveals that in 2022, only 18% of eligible individuals reported being up to date with recommended lung cancer screenings (LCS). This low uptake is particularly concerning in southern states, which also have high lung cancer mortality rates.
Key Findings
Low Screening Rates Nationwide
Despite the US Preventive Services Task Force’s recommendations, LCS rates remain low, with significant variability across states (9.7%-31%).
Socioeconomic and Access Disparities
The study found that individuals in states with Medicaid expansion and higher LCS capacity had better screening rates. However, uninsured individuals and those without a usual source of care had very low screening rates (3.7% and 5.1%, respectively).
Impact of Age and Comorbidities
Older individuals and those with multiple comorbidities were more likely to be up to date with LCS.
Implications for Lung Cancer Detection
These findings underscore the need for improved healthcare access and increased screening capacity to enhance early detection of lung cancer. At Cizzle Bio, Inc., they are committed to addressing these challenges with their CIZ1B biomarker test, aiming to make lung cancer screening more accessible and effective.
For more detailed information, you can read the article here.